Brought to you by 
CureVac lands $110mm in late-stage venture round
03 Nov 2015
Executive Summary
CureVac AG (cancer and infectious diseases) raised $110mm (€100mm) in a late-stage financing to lead investor Baillie Gifford (an investment management company), which was joined by other first-time backers Chartwave, Coppel family, Elma Investments, and Sigma Group, and returning shareholders dievini Hopp BioTech and the Bill & Melinda Gates Foundation. Proceeds will help the company expand its mRNA technology and continue development of its pipeline, which is led by Phase IIb CV9104 for prostate cancer. CureVac concurrently announced it changed from a German limited liability company (GMBH) to a joint German stock corporation (AG).
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
- Vaccines
-
Biotechnology
- Antisense, Oligonucleotides
- Large Molecule
-
Drug Discovery Technologies
- Genomics-Proteomics
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
CureVac lands $110mm in late-stage venture round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice